Juno Therapeutics Gmbh

Immune Design Corp.

Memorial Sloan Kettering Cancer Center

Immune Designcorp.

Semih Ullah Tareen

Christopher James Nicolai

Eric L Smith

Yan Chen

Steven M Shamah

Csaba Pazmany

Jui Dutta-Simmons

Rupesh Amin

Collin Hauskins

Blythe D Sather

Aye Chen

Melissa Works

Ruth Salmon

Rebecca Wu

Kimberly Harrington

Keenan Bashour

James Sissons

Mariana Cota Stirner

Allen Ebens

Erik Hess

Cyr De Imus

Jon Jones

Audrey Olshefsky

Stefan Ponko

Mark Frohlich

Provided herein are chimeric receptors, including chimeric antigen receptors (CARs), comprising BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof, including heavy chain variable (V) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, including a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof including in adoptive cell therapy.

Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides

Provided herein are methods for transducing a plurality of cells in a composition of cells, such as a population of lymphocytes, containing viral particles. In some aspects, provided methods and reagents for the transduction of cell populations involve binding of agents to a molecule on the surface of the cells. In some cases, the reagents are multimerization reagents and the one or more agents are multimerized by reversibly binding to the reagent. In some aspects, the multimerized agent can provide for transduction and/or expansion or proliferation or other stimulation of a population of cells, and then such agents can be removed by disruption of the reversible bond. Also provided are compositions, apparatus and methods of use thereof.

Methods, kits, agents and apparatuses for transduction

Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (V) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof such as in adoptive cell therapy.

Materials and methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein are provided.

Materials and methods for producing improved lentiviral vector particles

Provided are polynucleotides containing a modified PRE having a variant X gene that includes one or more stop codons not present in an unmodified, such as wild-type, hepatitis X gene. Also provided are polynucleotides containing a modified PRE having a variant X gene that includes one or more degradation sequences not present in an unmodified, such as wild-type, hepatitis X gene. The modified PRE can be operably linked to a nucleic acid encoding a recombinant protein. Also provided are expression cassettes, viral vectors and cells containing the polynucleotides, and compositions and methods of use thereof.

Modified hepatitis post-transcriptional regulatory elements

Materials and methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein are provided. More specifically, methods for generating such materials include culturing in a culture medium including kifunensine a virus packaging cell with a lentiviral vector genome including a polynucleotide encoding an exogenous antigen, a polynucleotide encoding a Sindbis E2 glycoprotein that preferentially binds dendritic cells expressing DC-SIGN, and a polynucleotide encoding a Vpx protein or a Vpr protein that retains SAMHD1-inhibiting activity, followed by isolating a pseudotyped lentiviral vector particle that preferentially binds dendritic cells expressing DC-SIGN.

Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein

Growing community of inventors

Seattle, WA, United States of America

Semih Ullah Tareen